BMRN BioMarin Pharmaceutical Inc. - Common Stock
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 6, 2026 10-K/10-Q Ago 6, 2026BMRN Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
BMRN Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Informazioni su BioMarin Pharmaceutical Inc. - Common Stock Panoramica della società da Wikipedia
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
History
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
Business development
In 2002, BioMarin acquired Glyko Biomedical.
In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders.
In November 2014, the company agreed to the acquisition of Prosensa for up to $840 million; however, the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in May 2016.
In October 2019 it was revealed that the group will open an office in Dublin to support further growth through Europe, the Middle East and Asia.
In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Products
As of 2022, BioMarin has six products on the market, each of which is an orphan drug.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria
Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI)
Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I
Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only)
Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.
Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022.
Biomarin is working to develop several new drugs.
Controversies
In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.
In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.
In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.
In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it. The company was criticised by the NHS and Stephen Hammond MP for patient profiteering. The company commented the following in response: "BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan, despite more than a decade of positive patient outcomes across 26 countries in Europe, Russia and Turkey"
In June 2019, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge. BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered, or until the medicine would be available on the Belgian market at a reasonable price.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | BMRN | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | 144.2media 5 anni ≈11.8 | ≈11.8 | · | · | |
| P/S (TTM) | 3.2media 5 anni ≈6.7 | ≈6.7 | 20.4 | Sottovalutato | |
| P/B (MRQ) | 1.7media 5 anni ≈3.2 | ≈3.2 | 11.3 | Sottovalutato | |
| Prezzo / FCF (TTM) | 14.7media 5 anni ≈152.1 | ≈152.1 | · | · | |
| Prezzo / Flusso di cassa (TTM) | 12.7media 5 anni ≈62.6 | ≈62.6 | · | · | |
| Prezzo / Valore contabile tangibile (MRQ) | 7.5media 5 anni ≈3.5 | ≈3.5 | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | BMRN | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | 4.4%media 5 anni ≈7.8% | ≈7.8% | -30.6% | Di prim'ordine | |
| Margine EBITDA (TTM) | 8.9%media 5 anni ≈12.0% | ≈12.0% | -30.6% | Di prim'ordine | |
| Margine ante imposte (TTM) | 4.4%media 5 anni ≈9.0% | ≈9.0% | -29.3% | Di prim'ordine | |
| Margine di Profitto Netto (TTM) | 2.1%media 5 anni ≈7.2% | ≈7.2% | -29.6% | Di prim'ordine | |
| ROA (TTM) | 0.76%media 5 anni ≈2.9% | ≈2.9% | -22.9% | Di prim'ordine | |
| ROE (TTM) | 1.2%media 5 anni ≈3.7% | ≈3.7% | 18.1% | Debole | |
| ROIC | 4.9%media 5 anni ≈3.2% | ≈3.2% | 14.3% | Debole |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | BMRN | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto (MRQ) | 0.7 | · | 0.3 | Debito elevato | |
| Rapporto corrente (MRQ) | 2.4media 5 anni ≈4.4 | ≈4.4 | 3.2 | Bassa liquidità | |
| Quick Ratio | 2.9media 5 anni ≈2.1 | ≈2.1 | 1.8 | Bassa liquidità | |
| Debito a lungo termine / Patrimonio netto (MRQ) | 0.6 | · | 0.6 | In linea |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | BMRN | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | 12.9%media 5 anni ≈11.8% | ≈11.8% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | 15.4%media 5 anni ≈13.4% | ≈13.4% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | 11.6% | · | · | · | |
| EPS YoY | -18.6%media 5 anni ≈50.5% | ≈50.5% | · | · | |
| Net Income YoY (Utile Netto YoY) | -18.3%media 5 anni ≈51.6% | ≈51.6% | · | · | |
| EPS CAGR 3Y (CAGR EPS 3 anni) | 33.9% | · | · | · | |
| EPS CAGR 5Y (CAGR EPS 5 anni) | -16.7% | · | · | · | |
| Net Income CAGR 3Y (CAGR Utile Netto 3 anni) | 35.1% | · | · | · | |
| Net Income CAGR 5Y (CAGR Utile Netto 5 anni) | -16.4% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | BMRN | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 0.4media 5 anni ≈0.4 | ≈0.4 | 0.4 | In linea | |
| Inventory Turnover (Rotazione delle scorte) | 0.6media 5 anni ≈0.6 | ≈0.6 | 1.0 | Sotto la media | |
| Receivables Turnover (Rotazione dei crediti) | 4.1media 5 anni ≈4.5 | ≈4.5 | 5.1 | Debole | |
| Revenue / Employee (Ricavi / Dipendente) | ≈$1.0M | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 3, 2026 | $0.73 | $0.70 | 4.0% |
| 31 Marzo 2026 | $0.54 | $0.77 | -29.5% | |
| 31 Dicembre 2025 | $-0.24 | $0.64 | -137.7% | |
| 30 Settembre 2025 | $-0.16 | $0.38 | -142.2% | |
| 30 Giugno 2025 | $1.23 | $0.85 | 44.4% | |
| 31 Marzo 2025 | $0.95 | $0.72 | 31.5% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $31.65 | $29.66 | $26.25 | $24.71 | $23.22 | $22.59 | $17.36 | $16.65 | $15.97 | $16.02 | $14.86 | $10.25 | |
| Revenue / Share | $16.32 | $14.51 | $12.63 | $11.09 | $10.10 | $9.71 | $9.52 | $8.41 | $7.53 | $6.72 | · | · | |
| Cash Flow / Share | $4.19 | $2.91 | $0.83 | $0.93 | $1.67 | $0.45 | $0.27 | $0.11 | $-0.05 | $-1.37 | · | · | |
| Cash / Share | $6.82 | $4.94 | $4.00 | $3.89 | $3.19 | $3.57 | $2.43 | $2.77 | $3.40 | $2.37 | $2.46 | $5.87 | |
| EPS (TTM) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | · | 192,032,000 | 191,907,000 | 190,967,000 | · | 190,429,000 | 190,114,000 | 188,866,000 | · | 188,219,000 | 187,948,000 | 186,667,000 | · | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | · | 192,032,000 | 197,091,000 | 196,474,000 | · | 197,147,000 | 200,505,000 | 199,262,000 | · | 191,173,000 | 194,998,000 | 194,363,000 | · | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | · |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | · | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | · | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | · | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | · | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | · | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | · | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | · |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | · | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | · | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | · |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | · |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $32.66 | $32.14 | · | $31.53 | $31.39 | $30.21 | · | $28.41 | $27.77 | $26.74 | · | $26.00 | $25.42 | $24.83 | · | · | |
| Revenue / Share | $5.09 | $3.88 | · | $4.04 | $4.19 | $3.79 | · | $3.78 | $3.55 | $3.26 | · | $3.04 | $3.05 | $3.07 | · | · | |
| Cash Flow / Share | · | $1.12 | · | · | · | $0.89 | · | · | · | $0.24 | · | · | · | $-0.38 | · | · | |
| Cash / Share | $4.52 | $11.50 | · | $6.51 | $6.32 | $5.47 | · | $3.54 | $5.11 | $3.94 | · | $4.17 | $3.69 | $3.09 | · | · | |
| EPS (TTM) | $0.39 | $1.39 | · | $2.67 | $3.38 | $2.70 | · | $1.66 | $1.32 | $1.06 | · | $0.78 | $0.53 | $0.39 | · | $0.43 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.41B | $3.24B | · | $3.09B | $3.06B | $2.95B | · | $2.75B | $2.59B | $2.47B | · | $2.31B | $2.23B | $2.17B | · | $2.01B | |
| Net Income TTM | $73M | $269M | · | $520M | $657M | $524M | · | $322M | $257M | $205M | · | $147M | $100M | $72M | · | $84M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | · | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 146.7 | 40.6 | · | 20.3 | 16.3 | 26.2 | · | 42.3 | 62.4 | 82.4 | · | 113.4 | 163.5 | 249.3 | · | 197.1 | |
| P/S | 3.3 | 3.4 | · | 3.4 | 3.4 | 4.6 | · | 4.9 | 6.1 | 6.7 | · | 7.2 | 7.3 | 8.4 | · | · | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | · | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| EV / Revenue | 4.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.68% | 2.5% | · | 4.9% | 6.2% | 3.8% | · | 2.4% | 1.6% | 1.2% | · | 0.88% | 0.61% | 0.40% | · | 0.51% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Margine Operativo % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| Utile netto | $349M | $427M | $168M | $142M | $-64M |
| EPS Diluito | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rapporto corrente | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $725M | $487M | $63M | $55M | $209M |
Proprietari istituzionali (13F) 614 filer · $12.2B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 89 (-16 vs trimestre precedente) | 75 (+10 vs trimestre precedente) | 209 (+1 vs trimestre precedente) | 198 (+29 vs trimestre precedente) | +10.2M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $1.169.875.004 | 20.445.212 | 9,56% | Azioni |
| VANGUARD GROUP INC | $1.077.337.946 | 18.127.847 | 8,80% | Azioni |
| Dodge & Cox | $849.426.895 | 14.844.930 | 6,94% | Azioni |
| PRIMECAP MANAGEMENT CO/CA/ | $811.962.329 | 14.190.183 | 6,63% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $500.310.680 | 8.743.633 | 4,09% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494.877.355 | 8.648.678 | 4,04% | Azioni |
| NORGES BANK | $469.659.128 | 8.207.954 | 3,84% | Azioni |
| STATE STREET CORP | $446.370.874 | 7.800.959 | 3,65% | Azioni |
| VIKING GLOBAL INVESTORS LP | $435.819.735 | 7.616.563 | 3,56% | Azioni |
| Vestal Point Capital, LP | $344.750.500 | 6.025.000 | 2,82% | Azioni |
| AQR CAPITAL MANAGEMENT LLC | $322.537.038 | 5.699.541 | 2,64% | Azioni |
| FMR LLC | $275.965.970 | 4.822.893 | 2,26% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $233.217.034 | 4.075.714 | 1,91% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $223.885.722 | 3.911.794 | 1,83% | Azioni |
| Capital Research Global Investors | $200.521.024 | 3.504.387 | 1,64% | Azioni |
| Deep Track Capital, LP | $189.254.063 | 3.307.481 | 1,55% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $118.549.312 | 2.071.816 | 0,97% | Azioni |
| Assenagon Asset Management S.A. | $100.826.561 | 1.762.086 | 0,82% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $92.468.664 | 1.616.020 | 0,76% | Azioni |
| FIRST TRUST ADVISORS LP | $91.910.897 | 1.606.273 | 0,75% | Azioni |
| NORTHERN TRUST CORP | $89.154.711 | 1.558.104 | 0,73% | Azioni |
| MORGAN STANLEY | $86.115.553 | 1.504.989 | 0,70% | Azioni |
| Jones Hill Capital LP | $81.915.580 | 1.431.590 | 0,67% | Azioni |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76.264.876 | 1.332.836 | 0,62% | Azioni |
| Swedbank AB | $75.232.112 | 1.314.787 | 0,61% | Azioni |
| UBS Group AG | $73.613.817 | 1.286.505 | 0,60% | Azioni |
| DNB Asset Management AS | $72.566.061 | 1.268.194 | 0,59% | Azioni |
| Caisse de depot et placement du Quebec | $70.749.440 | 1.236.446 | 0,58% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $70.030.356 | 1.223.879 | 0,57% | Azioni |
| GOLDMAN SACHS GROUP INC | $68.777.119 | 1.201.977 | 0,56% | Azioni |
| AMERIPRISE FINANCIAL INC | $66.255.506 | 1.157.865 | 0,54% | Azioni |
| Bank of New York Mellon Corp | $66.106.543 | 1.155.305 | 0,54% | Azioni |
| CITADEL ADVISORS LLC | $64.224.186 | 1.122.408 | 0,52% | Azioni |
| Balyasny Asset Management L.P. | $60.344.956 | 1.054.613 | 0,49% | Azioni |
| ARGA Investment Management, LP | $59.474.983 | 1.039.409 | 0,49% | Azioni |
| Brandywine Global Investment Management, LLC | $56.211.687 | 945.847 | 0,46% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54.484.884 | 952.200 | 0,45% | Opzione Call |
| FRANKLIN RESOURCES INC | $53.560.439 | 936.044 | 0,44% | Azioni |
| MACKENZIE FINANCIAL CORP | $53.321.258 | 931.864 | 0,44% | Azioni |
| JANUS HENDERSON GROUP PLC | $48.409.915 | 857.010 | 0,40% | Azioni |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $48.062.765 | 850.819 | 0,39% | Azioni |
| Hudson Bay Capital Management LP | $47.206.614 | 825.002 | 0,39% | Azioni |
| Russell Investments Group, Ltd. | $44.813.913 | 783.148 | 0,37% | Azioni |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $40.949.264 | 715.646 | 0,33% | Azioni |
| LOOMIS SAYLES & CO L P | $40.835.454 | 713.657 | 0,33% | Azioni |
| JPMORGAN CHASE & CO | $40.573.267 | 694.550 | 0,33% | Azioni |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39.869.980 | 696.784 | 0,33% | Azioni |
| Nuveen, LLC | $39.432.077 | 689.131 | 0,32% | Azioni |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39.311.857 | 687.030 | 0,32% | Azioni |
| Palo Alto Investors LP | $39.068.500 | 682.777 | 0,32% | Azioni |
Attivisti e proprietari del 5%+ 4 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 depositi | 02 Febbraio 2015 | · | Deposito iniziale | · | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 depositi | 31 Luglio 2009 | · | Deposito iniziale | · | SEC |
| 06 Giugno 2005 | · | Deposito iniziale | Campagna per il consiglio di amministrazione | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 depositi | 06 Maggio 2005 | · | Deposito iniziale | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 50 insider · 21 dirigenti · 30 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 17 Marzo 2026 F | 214.635 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | 02 Maggio 2005 A | 14.934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | 06 Maggio 2004 P | 79.285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | 17 Marzo 2026 F | 123.314 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | 30 Aprile 2019 A | 47.686 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | 14 Maggio 2012 M | 41.089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | 13 Settembre 2024 F | 185.074 | 0 | 0 | $0 |
| Robert Baffi | President, Global Mfg/Tech Ops | 20 Marzo 2020 F | 117.138 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | 30 Settembre 2026 F | 47.732 | 0 | 2 | $-558.646 |
| George Eric Davis | EVP, Chief Legal Officer | 02 Settembre 2026 S | 61.003 | 0 | 2 | $-2.762.781 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 20 Maggio 2026 F | 42.472 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 17 Marzo 2026 F | 84.140 | 0 | 1 | $-996.744 |
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | 20 Gennaio 2026 A | 25.610 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | 20 Maggio 2025 S | 14.173 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | 02 Maggio 2024 S | 66.767 | 0 | 0 | $0 |
| Andrea Acosta | GVP, Chief Accounting Officer | 16 Luglio 2021 F | 18.122 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | 02 Luglio 2012 M | 59.030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | 02 Marzo 2009 M | 39.621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | 07 Luglio 2008 A | 12.000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | 01 Dicembre 2005 M | 295.176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | 31 Ottobre 2004 A | 2.740 | 0 | 0 | $0 |
| Robert M Plenge | Direttore | 10 Settembre 2026 A | 6.140 | 0 | 0 | $0 |
| Elizabeth M Anderson | Direttore | 02 Giugno 2026 A | 41.940 | 0 | 0 | $0 |
| Barbara W. Bodem | Direttore | 02 Giugno 2026 A | 21.045 | 0 | 0 | $0 |
| Maykin Ho | Direttore | 02 Giugno 2026 A | 35.500 | 0 | 0 | $0 |
| Mark J Enyedy | Direttore | 02 Giugno 2026 A | 21.040 | 0 | 0 | $0 |
| Athena Countouriotis | Direttore | 02 Giugno 2026 A | 21.040 | 0 | 0 | $0 |
| Robert J. Hombach | Direttore | 02 Giugno 2026 A | 49.360 | 0 | 0 | $0 |
| Timothy P Walbert | Direttore | 02 Giugno 2026 A | 17.270 | 0 | 0 | $0 |
| Ian T Clark | Direttore | 02 Giugno 2026 A | 14.490 | 0 | 0 | $0 |
| Willard H Dere | Direttore | 02 Giugno 2026 A | 46.440 | 0 | 0 | $0 |
| Richard A Meier | Direttore | 20 Maggio 2025 A | 127.426 | 0 | 0 | $0 |
| Elaine J Heron | Direttore | 03 Giugno 2024 M | 97.720 | 0 | 0 | $0 |
| David E I Pyott | Direttore | 21 Maggio 2024 A | 49.750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Direttore | 20 Maggio 2024 F | 473.792 | 0 | 0 | $0 |
| Dennis Slamon | Direttore | 18 Marzo 2024 M | 31.299 | 0 | 0 | $0 |
| Mark J Alles | Direttore | 23 Maggio 2023 A | 15.095 | 0 | 0 | $0 |
| Bryan V Lawlis | Direttore | 23 Maggio 2023 A | 33.140 | 0 | 0 | $0 |
| Michael G Grey | Direttore | 05 Marzo 2021 M | 42.840 | 0 | 0 | $0 |
| Alan Lewis | Direttore | 04 Giugno 2019 A | 25.590 | 0 | 0 | $0 |
| Kathryn E Falberg | Direttore | 15 Luglio 2016 A | 2.640 | 0 | 0 | $0 |
| William D Young | Direttore | 10 Giugno 2015 A | 11.875 | 0 | 0 | $0 |
| Kenneth Bate | Direttore | 10 Giugno 2015 A | 11.875 | 0 | 0 | $0 |
| Pierre Lapalme | Direttore | 10 Giugno 2015 A | 31.250 | 0 | 0 | $0 |
| Joseph Klein III | Direttore | 08 Marzo 2010 S | 35.000 | 0 | 0 | $0 |
| Franz L Cristiani | Direttore | 14 Giugno 2006 A | · | 0 | 0 | $0 |
| Erich Sager | Direttore | 24 Febbraio 2006 M | 3.309 | 0 | 0 | $0 |
| Gwynn Williams | Direttore | 30 Novembre 2004 A | 812.565 | 0 | 0 | $0 |
| John Urquhart | Direttore | 28 Luglio 2004 A | · | 0 | 0 | $0 |
| Mark Wood | · | 22 Maggio 2013 M | 20.277 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 81 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,44% | 177.878 SH | 05 Ottobre 2026 | Giornaliero |
| BBP · ETFis Series Trust I | 1,48% | 24.255 NS | 31 Luglio 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,31% | 15.080 NS | 31 Luglio 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,17% | 41.384 NS | 31 Luglio 2026 | N-PORT |
| RNIN · EA Series Trust | 1,15% | 35.050 NS | 31 Luglio 2026 | N-PORT |
| IBB · iShares Trust | 0,92% | 1.454.497 SH | 11 Settembre 2026 | Giornaliero |
| CALF · Pacer Funds Trust | 0,79% | 482.285 NS | 31 Luglio 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,76% | 30.936 NS | 31 Luglio 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,74% | 13.836 SH | 05 Ottobre 2026 | Giornaliero |
| LABU · Direxion Shares ETF Trust | 0,73% | 60.076 NS | 31 Luglio 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,44% | 77.415 NS | 31 Luglio 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,44% | 24.133 NS | 31 Luglio 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,36% | 26.107 SH | 05 Ottobre 2026 | Giornaliero |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 108.709 SH | 19 Agosto 2026 | Giornaliero |
| PTMC · Pacer Funds Trust | 0,33% | 21.272 NS | 31 Luglio 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,32% | 436.803 NS | 31 Luglio 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,30% | 2.559.860 SH | 19 Agosto 2026 | Giornaliero |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,30% | 312.378 SH | 19 Agosto 2026 | Giornaliero |
| BKMC · BNY Mellon ETF Trust | 0,28% | 29.895 NS | 31 Luglio 2026 | N-PORT |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,27% | 71.381 SH | 19 Agosto 2026 | Giornaliero |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,25% | 84.704 NS | 31 Luglio 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,25% | 2.838 NS | 31 Luglio 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,20% | 821 NS | 31 Luglio 2026 | N-PORT |
| IYH · iShares Trust | 0,20% | 111.984 SH | 11 Settembre 2026 | Giornaliero |
| SMMD · iShares Trust | 0,17% | 102.244 SH | 11 Settembre 2026 | Giornaliero |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,17% | 16.041 NS | 31 Luglio 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,16% | 19.998 SH | 19 Agosto 2026 | Giornaliero |
| DFAS · Dimensional ETF Trust | 0,16% | 401.829 NS | 31 Luglio 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,15% | 84.531 NS | 31 Luglio 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,15% | 534.462 SH | 19 Agosto 2026 | Giornaliero |
| ISCG · iShares Trust | 0,15% | 21.366 SH | 11 Settembre 2026 | Giornaliero |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 20.990 SH | 19 Agosto 2026 | Giornaliero |
| ESML · iShares Trust | 0,13% | 56.252 SH | 11 Settembre 2026 | Giornaliero |
| VB · VANGUARD INDEX FUNDS | 0,13% | 4.433.137 SH | 19 Agosto 2026 | Giornaliero |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,13% | 28.086 SH | 05 Ottobre 2026 | Giornaliero |
| IWS · iShares Trust | 0,12% | 286.469 SH | 11 Settembre 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,12% | 2.217.617 SH | 19 Agosto 2026 | Giornaliero |
| WSML · iShares Trust | 0,11% | 11.104 SH | 11 Settembre 2026 | Giornaliero |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3.901 NS | 31 Luglio 2026 | N-PORT |
| PEXL · Pacer Funds Trust | 0,09% | 797 NS | 31 Luglio 2026 | N-PORT |
| IWR · iShares Trust | 0,09% | 787.222 SH | 11 Settembre 2026 | Giornaliero |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,08% | 11.540 SH | 05 Ottobre 2026 | Giornaliero |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,08% | 18.000 NS | 31 Luglio 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 5.934 NS | 31 Luglio 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,06% | 143.957 NS | 31 Luglio 2026 | N-PORT |
| FBUF · Fidelity Greenwood Street Trust | 0,05% | 212 NS | 31 Luglio 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 4.814 NS | 31 Luglio 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,05% | 18.819 NS | 31 Luglio 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,05% | 40.903 SH | 05 Ottobre 2026 | Giornaliero |
| DFAC · Dimensional ETF Trust | 0,04% | 347.063 NS | 31 Luglio 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,03% | 19.135 NS | 31 Luglio 2026 | N-PORT |
| IWD · iShares Trust | 0,03% | 425.477 SH | 11 Settembre 2026 | Giornaliero |
| DSI · iShares Trust | 0,03% | 27.701 SH | 11 Settembre 2026 | Giornaliero |
| REVS · Columbia ETF Trust I | 0,03% | 1.740 NS | 31 Luglio 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 115.700 SH | 19 Agosto 2026 | Giornaliero |
| DFUV · Dimensional ETF Trust | 0,03% | 74.321 NS | 31 Luglio 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,03% | 45.178 SH | 05 Ottobre 2026 | Giornaliero |
| TILT · FlexShares Trust | 0,03% | 9.322 NS | 31 Luglio 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,02% | 3.375 NS | 31 Luglio 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,02% | 44.514 NS | 31 Luglio 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 6.143.206 SH | 19 Agosto 2026 | Giornaliero |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 31.861 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 16.031 SH | 19 Agosto 2026 | Giornaliero |
| ESGV · VANGUARD WORLD FUND | 0,02% | 43.345 SH | 19 Agosto 2026 | Giornaliero |
| IUSG · iShares Trust | 0,02% | 97.914 SH | 11 Settembre 2026 | Giornaliero |
| IWB · iShares Trust | 0,02% | 130.403 SH | 11 Settembre 2026 | Giornaliero |
| IYY · iShares Trust | 0,02% | 8.059 SH | 11 Settembre 2026 | Giornaliero |
| ITOT · iShares Trust | 0,02% | 253.576 SH | 11 Settembre 2026 | Giornaliero |
| IUSV · iShares Trust | 0,02% | 71.403 SH | 11 Settembre 2026 | Giornaliero |
| RECS · Columbia ETF Trust I | 0,02% | 16.398 NS | 31 Luglio 2026 | N-PORT |
| IWV · iShares Trust | 0,02% | 51.240 SH | 11 Settembre 2026 | Giornaliero |
| DFUS · Dimensional ETF Trust | 0,02% | 53.858 NS | 31 Luglio 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 169.270 SH | 19 Agosto 2026 | Giornaliero |
| DFLV · Dimensional ETF Trust | 0,00% | 1.028 NS | 31 Luglio 2026 | N-PORT |
| IJH · iShares Trust | · | 6.782.201 SH | 11 Settembre 2026 | Giornaliero |
| IJK · iShares Trust | · | 638.802 SH | 11 Settembre 2026 | Giornaliero |
| IJJ · iShares Trust | · | 423.789 SH | 21 Agosto 2026 | Giornaliero |
| XJH · iShares Trust | · | 26.404 SH | 08 Settembre 2026 | Giornaliero |
| ISCB · iShares Trust | · | 8.699 SH | 11 Settembre 2026 | Giornaliero |
| ISCV · iShares Trust | · | 27.848 SH | 11 Settembre 2026 | Giornaliero |
| SMMV · iShares Trust | · | 29.688 SH | 19 Agosto 2026 | Giornaliero |
BMRN Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
Target Price a 12 Mesi
26 analisti · 2026-10-02Target medio $91.62 +63,0%
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | · |
| SMMT | $13.56B | -12.1 | · | · | -235.1% | · |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | · |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | · |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | · |
| IBRX | $2.00B | -5.2 | 668.3% | -310.2% | 71.0% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | · |
Ultime notizie Notizie recenti che menzionano questa società
Segnali di trading Segnali recenti di acquisto/vendita con prezzo di entrata e rapporto rischio/rendimento
Nessun segnale aperto al momento — nessuna scheda è compilata, e questo è onesto.
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.